184 related articles for article (PubMed ID: 31961236)
21. Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
Oda Y; Fujita Y; Oishi K; Nakata Y; Takase M; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Psychopharmacology (Berl); 2017 Oct; 234(20):3027-3036. PubMed ID: 28744562
[TBL] [Abstract][Full Text] [Related]
22. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
Kelley ME; Yao JK; van Kammen DP
Neuropsychopharmacology; 1999 Jun; 20(6):603-11. PubMed ID: 10327429
[TBL] [Abstract][Full Text] [Related]
23. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
24. Schizophrenia and dopamine receptors.
Seeman P
Eur Neuropsychopharmacol; 2013 Sep; 23(9):999-1009. PubMed ID: 23860356
[TBL] [Abstract][Full Text] [Related]
25. Extended (alternate day) antipsychotic dosing and dopamine supersensitivity psychosis: A case report.
Kumar V; Venkatasubramanian G
Schizophr Res; 2017 Jul; 185():204-205. PubMed ID: 28089134
[No Abstract] [Full Text] [Related]
26. Dopamine D2 receptors as treatment targets in schizophrenia.
Seeman P
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
[TBL] [Abstract][Full Text] [Related]
27. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
[TBL] [Abstract][Full Text] [Related]
28. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Chouinard G; Jones BD
Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
[TBL] [Abstract][Full Text] [Related]
29. Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls.
Goto N; Yoshimura R; Kakeda S; Moriya J; Hayashi K; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Korogi Y; Nakamura J
Eur Psychiatry; 2011 Jan; 26(1):57-63. PubMed ID: 20434315
[TBL] [Abstract][Full Text] [Related]
30. Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats.
Kimura M; Oda Y; Oishi K; Yoshino K; Kimura H; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Schizophr Res; 2021 Feb; 228():1-6. PubMed ID: 33429150
[TBL] [Abstract][Full Text] [Related]
31. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
Simon N; Azorin JM
Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
[TBL] [Abstract][Full Text] [Related]
32. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia.
Nakata Y; Kanahara N; Kimura H; Watanabe H; Iyo M
Int Clin Psychopharmacol; 2017 May; 32(3):169-173. PubMed ID: 28067751
[TBL] [Abstract][Full Text] [Related]
34. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis.
Fallon P; Dursun SM
J Psychopharmacol; 2011 Jun; 25(6):755-62. PubMed ID: 20147573
[TBL] [Abstract][Full Text] [Related]
35. Is schizophrenia a dopamine supersensitivity psychotic reaction?
Seeman MV; Seeman P
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():155-60. PubMed ID: 24128684
[TBL] [Abstract][Full Text] [Related]
36. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
Takeuchi H; Siu C; Remington G; Fervaha G; Zipursky RB; Foussias G; Agid O
Neuropsychopharmacology; 2019 May; 44(6):1036-1042. PubMed ID: 30514883
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.
Yoshimura R; Ueda N; Shinkai K; Nakamura J
Int Clin Psychopharmacol; 2003 Mar; 18(2):107-11. PubMed ID: 12598823
[TBL] [Abstract][Full Text] [Related]
38. Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine.
Takao N; Murai T; Fujiwara H
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33849886
[TBL] [Abstract][Full Text] [Related]
39. G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis.
Oda Y; Tadokoro S; Takase M; Kanahara N; Watanabe H; Shirayama Y; Hashimoto K; Iyo M
J Psychopharmacol; 2015 Dec; 29(12):1308-13. PubMed ID: 26174132
[TBL] [Abstract][Full Text] [Related]
40. Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [
Kim S; Shin SH; Santangelo B; Veronese M; Kang SK; Lee JS; Cheon GJ; Lee W; Kwon JS; Howes OD; Kim E
Mol Psychiatry; 2021 Jul; 26(7):3476-3488. PubMed ID: 32929214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
